PRN: Asia-Pacific Asthma Market Hit $3.5 Billion in 2014 and Will Reach $5.6 Billion by 2021, Says GBI Research

08/mar/2016 16.00.41 PR Newswire Turismo Contatta l'autore

Questo comunicato è stato pubblicato più di 1 anno fa. Le informazioni su questa pagina potrebbero non essere attendibili.

Asia-Pacific Asthma Market Hit $3.5 Billion in 2014 and Will Reach $5.6 Billion by 2021, Says GBI Research

 
[08-March-2016]
 

LONDON, March 8, 2016 /PRNewswire/ --

A new report from business intelligence provider GBI Research - Asthma Therapeutics in Asia-Pacific Markets to 2021 - states that the asthma therapeutics market in the Asia-Pacific (APAC) region will grow from $3.5 billion in 2014 to $5.6 billion by 2021, at a strong Compound Annual Growth Rate (CAGR) of 7.2%.

The primary driver of this considerable rise is the prevalence of asthma across the APAC countries, which include China, India, Australia, South Korea, and Japan. The condition is burgeoning due to aging populations and increases in air pollution, dust and pollen levels, which both cause and exacerbate asthma in children.

Analyst Aswini Nath says: "As well as the increasing incidence of the disease, six costly biologics are set to enter the APAC asthma market which will push its value up considerably. These consist of GlaxoSmithKline's, mepolizumab, Teva's reslizumab, Chugai/Roche's lebrikizumab, Sanofi/Regeneron's dupilumab, and AstraZeneca's tralokinumab and benralizumab.

"The most advanced of these drugs is mepolizumab, which is currently at the Pre-registration stage in Japan, while the other five monoclonal antibodies (mAbs) are in Phase III development in the APAC region. As the cost of these treatments is likely to be high in comparison with more established drugs, strong uptake could well increase the cost of treatment for asthma patients."

GBI Research also states that India has the highest number of asthma sufferers of the five APAC countries. In 2014, 53.6 million people were estimated to be living with the disease, which is approximately 52.4% of the total assessed Asia-Pacific prevalence.

Nath elaborates: "Lack of knowledge of the disease condition among the public, an increasing aging population, and increasing air and dust pollution will mean the prevalence rate will continue to rise over the period, resulting in 57 million sufferers by 2021.

"Despite this, India only represented 12.2% of the APAC asthma market in 2014, which reflects the low cost of therapy in comparison with the other assessed countries."

Japan, by contrast, was the largest market of the five APAC countries in 2014 at $1.8 billion, and will continue its lead to 2021, growing to $3 billion at a CAGR of 7.1%.

"As Japan is ranked only third of the five countries in terms of disease prevalence, this reflects the relatively high cost of drugs, and the country's readiness to adopt promising new molecules such as the IL-targeting mAbs," the analyst concludes.

Sample pages of GBI Research's report Asthma Therapeutics in Asia-Pacific Markets to 2021 are available upon request

About GBI Research

GBI Research is a leading provider of business intelligence reports, offering actionable data and forecasts based on the insights of key healthcare industry influencers to ensure you stay up-to-date with the latest market trends. Connect with GBI Research on social media for the latest healthcare market updates: Facebook | LinkedIn | Twitter

For more information about our offerings, please contact us on:

+44(0)161-359-5817

 

blog comments powered by Disqus
Comunicati.net è un servizio offerto da Factotum Srl